Prognostic Values of Various Clinical Factors and Genetic Subtypes for Diffuse Large B-cell lymphoma Patients: A Retrospective Analysis of 227 Cases

• Published in: Asian Pacific journal of cancer prevention : APJCP Vol. 14; no. 2; pp. 929 - 934
• Main Authors: Zhou, De, Xie, Wan-Zhuo, Hu, Ke-Yue, Huang, Wei-Jia, Wei, Guo-Qing, He, Jing-Song, Shi, Ji-Min, Luo, Yi, Li, Li, Zhu, Jing-Jing, Zhang, Jie, Lin, Mao-Fang, Ye, Xiu-Jin, Cai, Zhen, Huang, He
• Format: Journal Article
• Language: Korean
• Published: 2013
• Subjects: genetic subtypes; overall survival; prognostic analysis; rituximab; Diffuse large B-cell lymphoma
• ISSN: 1513-7368; 2476-762X

Aim: To analyze the significance of different clinical factors for prognostic prediction in diffuse large B-cell lymphoma (DLBCL) patients. Methods: Two hundred and twenty-seven DLBCL patients were retrospectively reviewed. Patients were managed with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen or rituximab plus the CHOP (RCHOP) regimen. Results: Lactate dehydrogenase (LDH), ${\beta}2$-microglobulin (${\beta}2$-M), B symptoms, Ann Arbor stage and genetic subtypes were statistically relevant in predicting the prognosis of the overall survival (OS). In the CHOP group, the OS in patients with germinal center B-cell-like (GCB)(76.2%) was significantly higher than that of the non-GCB group (51.9%, P=0.032). With RCHOP management, there was no statistical difference in OS between the GCB (88.4%) and non-GCB groups (81.9%, P=0.288). Conclusion: Elevated LDH and ${\beta}2$-M levels, positive B symptoms, Ann Arbor stage III/IV, and primary nodal lymphoma indicate an unfavorable prognosis of DLBCL patients. Patients with GCB-like DLBCL have a better prognosis than those with non-GCB when treated with the CHOP regimen. The RCHOP treatment with the addition of rituximab can improve the prognosis of patients with DLBCL.